Arcus Biosciences, Inc.
RCUS
$10.53
$0.050.48%
NYSE
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 471.43% | 7.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 471.43% | 7.69% | |||
| Cost of Revenue | 13.93% | 20.79% | |||
| Gross Profit | 122.34% | -25.33% | |||
| SG&A Expenses | 3.57% | 0.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.00% | 16.28% | |||
| Operating Income | 93.44% | -18.45% | |||
| Income Before Tax | 100.00% | -20.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 100.00% | -19.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 100.00% | -19.15% | |||
| EBIT | 93.44% | -18.45% | |||
| EBITDA | 94.96% | -19.00% | |||
| EPS Basic | 0.00% | -11.03% | |||
| Normalized Basic EPS | 100.00% | -12.23% | |||
| EPS Diluted | 0.00% | -11.03% | |||
| Normalized Diluted EPS | 100.00% | -12.23% | |||
| Average Basic Shares Outstanding | 7.83% | 7.31% | |||
| Average Diluted Shares Outstanding | 8.23% | 7.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||